Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: SEC Gensler continues to express concern over SPACs; Revelation Biosciences receives approval to conduct Phase 2b viral challenge study
SEC’s Gensler Talks Up Crypto and SPAC Regulations
Securities and Exchange Commission Chairman Gary Gensler shed light on an array of hot-button topics during an interview on Monday, expressing his belief that “people will be hurt” if cryptocurrency markets are allowed operate beyond the remit of regulators, and voicing concerns that SPACs leave public market investors vulnerable.
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99
Revelation Biosciences Inc., a clinical-stage life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study.
The Phase 2b, randomized, double-blind, influenza viral challenge study is planned in healthy volunteers. This viral challenge investigation will evaluate the potential efficacy of a single- and repeat-dose of REVTx-99 prophylaxis versus placebo on viral load and clinical illness influenza symptoms.
On August 30th, Revelation Biosciences entered into a definitive agreement to combine with Petra Acquisition, Inc. (NASDAQ:PAIC).
READ
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....